Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive after two years compared to 48.6% in the control group. Analysts are optimistic about its potential to transform non-small cell lung cancer therapy and capture a substantial share of the global market, though the company's stock saw a slight dip. AI
RANK_REASON Clinical trial results for a drug are presented. [lever_c_demoted from research: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
